Cracking the Code: The PANS/PANDAS Insurance Playbook

 

Introduction
If you’re navigating PANS/PANDAS, you know the "Boss Level" isn't the diagnosis—it’s the insurance company. It’s a world where life-changing treatments like IVIG are often dismissed as "investigational," leaving families and clinicians stuck in a loop of denials.

Our goal today is to help you speak "Insurer." By aligning your documentation with their specific criteria, we can move from "Denied" to "Approved."


Why Coverage is a Moving Target

Insurers don't treat patients; they process data. While clinical frameworks (like those from the PANS Research Consortium) prioritize severity, insurers prioritize codes and criteria.

Treatment CategoryPayer PerspectiveThe Strategy
AntibioticsGenerally covered if linked to infection.Document the specific bacterial trigger.
SteroidsHigh familiarity; usually easy to cover.Use as a "step-therapy" baseline for IVIG.
IVIGHighly Volatile. Often labeled "unproven."Requires objective severity scales (CY-BOCS).
PlasmapheresisVaries by state and specific plan.Reference ASFA Category II for PANDAS.

5 Common "Fail Points" (And how to dodge them)

  1. The "Investigational" Stamp: Some policies have a blanket "no" on PANS. You must pivot to "Medical Necessity" via an appeal.

  2. Lack of "Objective" Data: If it isn’t measured, it didn't happen. Use validated scales (e.g.CY-BOCS -"gold standard" for measuring OCD severity in children (ages 6–17).

  3. The Wrong "Lane": Many IVIG denials happen because the request went to Medical benefits instead of Pharmacy (PBM). Submit to both!

  4. Coding Mismatches: Sometimes the diagnosis code (D89.89) doesn't "talk" to the procedure code (36514) in their software.

  5. Missing Step-Therapy: Insurers want to see that you tried the "cheaper" stuff (NSAIDs, steroids) first.

  

The Practical Playbook: Step-by-Step


Step 1: Build Your "Coverage Dossier"

Before hitting submit, ensure you have a one-page "Executive Summary" including:

  • The Timeline: Abrupt onset date and functional impairment (e.g., "Inability to eat" or "School refusal").

  • The Exclusions: A list of other things you’ve already ruled out.

  • The Scores: Your baseline symptom scales.


Step 2: The "High-Yield" Move

Submit the Prior Authorization (PA) to both the Medical insurer and the Pharmacy Benefit Manager (PBM). This is often the "secret sauce" for getting IVIG approved.


Step 3: Strategic Peer-to-Peer

If a clinician does a Peer-to-Peer review, don't debate the existence of PANS. Instead:

  • Ask: "Which specific policy criteria are driving this denial?"

  • Response: "On page 4 of the chart, you’ll see we met that specific criterion by..."


Step 4: The Internal Appeal

Keep it factual, not emotional. Quote the plan’s own "medical necessity" definition back to them and show—line by line—how the patient qualifies.


The "Copy-Paste" Cheat Sheet

Use these structural phrases in your letters to align with insurance logic:

The Diagnosis Statement: "Patient meets PANS/PANDAS diagnostic criteria with abrupt onset (<1 month) of OCD and/or severely restricted food intake plus acute neuropsychiatric symptoms; alternative etiologies have been ruled out."

The Severity Statement: "Baseline severity documented with [CY-BOCS score]. These instruments will be repeated post-treatment to quantify response for reauthorization."

The Urgency Clause: "This request should be processed as expedited due to the risk of serious clinical deterioration and loss of function with prolonged delay."

Coding Reference (Verify with your billing team)

  • PANDAS: D89.89

  • PANS: D89.9

  • TPE (Plasmapheresis): CPT 36514

  • IVIG Supply: Common J-Codes include J1561 or J1569.

🔗 Recommended Resources

  • CMS.gov: For external review rights and timelines.

  • The Neuroimmune Foundation: For detailed "medical vs. pharmacy" benefit strategies








Created with